Home
Home

Theravance

Theravance Looks to Reward Shareholders by Splitting Into Two Distinct Companies

Theravance Looks to Reward Shareholders by Splitting Into Two Distinct Companies
Motley Fool

Did Elan Just Overpay On Theravance To Spurn Its Hostile Suitor?

Did Elan Just Overpay On Theravance To Spurn Its Hostile Suitor?
Forbes

Elan enters $1 billion royalty deal with Theravance over potential respiratory drug sales

Elan enters $1 billion royalty deal with Theravance over potential respiratory drug sales
Yahoo/AP

This Week in Biotech

This Week in Biotech
Motley Fool

Breo Ellipta gains US approval for the treatment of COPD

Breo Ellipta gains US approval for the treatment of COPD
Yahoo/PR Newswire

FDA approves Breo Ellipta to treat chronic obstructive pulmonary disease

FDA approves Breo Ellipta to treat chronic obstructive pulmonary disease
Yahoo/Fly on the Wall

3 Biotech Companies Ripe for a Takeover

3 Biotech Companies Ripe for a Takeover
Motley Fool

This Week in Biotech

This Week in Biotech
Motley Fool

Theravance to Split After Ending Review of Alternatives

Theravance to Split After Ending Review of Alternatives
Bloomberg

Theravance to split into two listed companies

Theravance to split into two listed companies
Reuters